Ilaris (Canakinumab) Receives a New Indication for the Treatment of Systemic Juvenile Idiopathic Arthritis
Systemic juvenile idiopathic arthritis (SJIA) is a rare inflammatory disease, affecting approximately 10% of children diagnosed with juvenile idiopathic arthritis in the United States.1,2 The classic symptoms of SJIA include pain in the small joints of the hands, wrists, knees, and ankles; rash; and a high, spiking fever of ≥103°F that can last for weeks to months.3 By definition, SJIA can present at any point until the age of 16 years.
Two studies presented at the 73rd Scientific Sessions of the American Diabetes Association, held in Chicago, demonstrate the value of telephone intervention delivered by primary care practices or trained health educators in preventing weight gain in persons at risk for developing diabetes and controlling blood glucose levels in patients with diabetes living in underserved areas.
Symptomatic hypoglycemic episodes, regardless of their severity, in patients with type 2 diabetes is associated with excess cardiovascular risk and all-cause mortality, according to Taiwanese researchers. They published their findings in the April issue of Diabetes Care (2013;36:894-900).
Weight Loss Intervention Fails to Reduce Cardiovascular Events in Type 2 Diabetes, but Has Positive Effect on Other Measures
Although an intensive lifestyle intervention (ILI) designed for weight loss did not reduce the risk of cardiovascular (CV) events after a decade in overweight/obese patients with type 2 diabetes compared with diabetes support and education (DSE), it did reduce the risk of the development of advanced kidney disease and depression, and it resulted in a lower rate of hospitalizations.
Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
Prostate cancer is the second leading cause of cancer-related death in the United States among men and the most frequently diagnosed cancer in American males. Among patients with metastatic prostate cancer, up to approximately 90% have bone metastases.1 The median survival after the diagnosis of bone metastasis associated with prostate cancer is approximately 3 years.2
Kadcyla (Ado-Trastuzumab Emtansine): First Antibody-Drug Conjugate Approved for the Treatment of HER2-Positive Metastatic Breast Cancer
Approximately 25% of women who are diagnosed with breast cancer have HER2-positive tumors. The HER2 gene, which resides on chromosome 17, directs tumor cells to manufacture HER2 protein. This protein is a cell-surface receptor that compels the tumor cell to grow and to divide more frequently than normal, making HER2-positive breast cancer an aggressive phenotype.
Before the advent of HER2-directed therapies, patients diagnosed with HER2-positive disease had significantly shorter disease-free survival compared with patients with other breast cancer subtypes.1
A consensus report on hypoglycemia and diabetes from the American Diabetes Association (ADA) and the Endocrine Society defines iatrogenic hypoglycemia as any episode of an abnormally low plasma glucose concentration that exposes the patient to potential harm. The workgroup also recommends individualization of glycemic targets based on several factors. It emphasizes that patients with type 2 diabetes might be particularly vulnerable to adverse events associated with hypoglycemia, including an increased risk of subsequent mortality and cardiovascular mortality.
Despite 1 in 3 American adults having prediabetes, only 11% report being told that they have prediabetes, according to researchers from the Division of Diabetes Translation at the US Centers for Disease Control and Prevention (CDC). The finding comes from an analysis of 3 sampling cycles of the National Health and Nutrition Examination Surveys (NHANES).
Intensive glucose control in patients with type 2 diabetes can reduce the risk of progression to end-stage renal disease but the number needed to treat is large, according to a post hoc analysis of the ADVANCE trial. The analysis appears in Kidney International (2013;83:517-524).
Achieving glucose, blood pressure, and lipid targets improving among diabetic patients, but there’s still long way to go
Management of blood glucose, blood pressure, and lipids in patients with diabetes has improved markedly over the past decade, but achievement of goal levels is still suboptimal.
Only about half of patients achieved the American Diabetes Association (ADA) targets for each of these measures in the period from 2007 to 2010, and fewer than 1 in 5 achieved all 3 of the goals, according to data from the National Health and Nutrition Examination Surveys (NHANES).
Page 10 of 19
Results 91 - 100 of 188
Results 91 - 100 of 188